A prospective, single-arm study to evaluate the efficacy and safety of Zoladex [goserelin] 3.6mg combined with CEF [cyclophosphamide, epirubicin, fluorouracil] chemotherapy as neo-adjuvant therapy in hormone responsive, premenopausal, operable breast cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Goserelin (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Therapeutic Use
- 17 Jul 2007 New trial record.